Berlin, August 22, 2018 – Medios AG (“Medios”) one of the leading Specialty Pharma companies in Germany, continued its growth course in the first half of 2018 and confirms its forecast for fiscal year 2018. According to preliminary calculations, Group sales rose by 24% to EUR 145 million in the first six months of the financial year (IFRS; previous year: EUR 117.0 million). Group earnings before taxes (EBT) increased by 21.5% to 4.7 million euros (IFRS; previous year: EUR 3.9 million), without taking account of the stock option program (SOP) adopted by resolution in 2017 and before non-recurring expenses associated with the commissioning of the laboratories acquired in September 2017. After non-recurring expenses, amounting to approx. 0.6 million euros, EBT excluding the SOP improved by 5.1%, to 4.1 million euros.
Manfred Schneider, CEO of Medios AG: “The high level of demand for individualized medicine continues unabated and is a key driver of our dynamic growth trend. Following the integration of the essential operating units of BerlinApotheke into Medios Individual, we have further expanded our specialty pharma spectrum and also achieved an improvement in profitability”.
The integration of essential operating units of BerlinApotheke Schneider & Oelski oHG into the Medios Group has largely been concluded since June 1, 2018. As expected, the profitability of the company Medios Individual GmbH will improve appreciably as a result of this strategic measure.
Matthias Gärtner, CFO of Medios AG: “All Medios Group companies reflect a highly encouraging development. In June alone, consolidated sales exceeded 28 million euros and earnings before taxes came to approx. 1 million euros, without taking account of the non-recurring and non-cash effects of the stock option program. Accordingly, we are clearly on track to reach our targets for the full-year 2018 and to establish Medios as the leading Specialty Pharma company in Germany.”
Against the backdrop of the positive development in the first half of 2018 and the planned further extension of operations, the Management of Medios AG confirms its forecast presented in March 2018. Consolidated sales in fiscal year 2018 are to improve to around 320 million euros and EBT (excluding the SOP) to approx. 11 million euros. This corresponds to growth rates of 26 percent and 37 percent, compared with business figures for 2017, reaching 253 million euros and 8.0 million euros, respectively.
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Kirchhoff Consult AG
Anja Ben Lekhal
Telephone: +49 40 60918655
Fax: +49 40 60918660
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.